Natixis Advisors LLC Acquires 7,084 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Natixis Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 120,109 shares of the biopharmaceutical company’s stock after buying an additional 7,084 shares during the quarter. Natixis Advisors LLC owned about 0.11% of Regeneron Pharmaceuticals worth $67,534,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of REGN. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Caitlin John LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $34,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $38,000. Finally, Berbice Capital Management LLC grew its position in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Finally, Canaccord Genuity Group lifted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $759.82 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company’s 50 day moving average price is $770.81 and its two-hundred day moving average price is $689.44. The stock has a market cap of $80.33 billion, a P/E ratio of 18.28, a P/E/G ratio of 2.04 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the business posted $12.07 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.